Atara Biotherapeutics Inc.'s backers proved less than happy with the phase III delay for the T-cell immunotherapy tab-cel (tabelecleucel), but the company remained upbeat about prospects with the compound in patients with Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD, or lymphomas that develop after a transplant).